Danaher Corporation heads into its May 5 Q1 report with short sellers meaningfully more active than they were a month ago — a notable shift for a stock where positioning had been quiet.
Short interest has nearly doubled over the past month. It climbed to 1.39% of the free float by the end of April, up roughly 85% from late March levels of around 0.72%. The acceleration accelerated sharply in the week of April 23, when short interest jumped 20% in five sessions. The borrow market remains loose — availability is ample and the cost to borrow is near 0.19% — so the build reflects fresh conviction from bears rather than a squeeze-driven unwind. The ORTEX short score of 29.5 ranks in the 84th percentile, flagging above-average short positioning pressure relative to the broader universe.
Options traders have also shifted more defensive. The put/call ratio has been running above 0.97 for the past week, well above its 20-day average of 0.83. The z-score of 1.07 is not extreme, but the direction is clear: the tone in the options market turned more cautious right after DHR reported Q1 results on April 21, when the stock fell nearly 6% in a single session and lost 8.5% over the following five days. The stock is down 7.6% on the month, closing at $175.15 on Friday — a level that now sits materially below all recent analyst price targets.
The bull-bear debate centres on the pace of the life sciences recovery. Bulls point to growing performance obligations, an expected ramp in the life sciences segment, and a resilient respiratory franchise. Bears focus on slowing revenue conversion — only 46% of near-term obligations were expected to convert within a year, down from 48% the prior quarter — alongside continued uncertainty in China and weaker-than-expected biotechnology revenue guidance. The sell-side remains firmly constructive in rating terms, with 19 buys and 3 outperforms against no sells. But a wave of target cuts has arrived ahead of this print: Morgan Stanley, Goldman Sachs, UBS, Wells Fargo, Barclays, and Guggenheim all lowered targets in April, trimming a range that now clusters between $212 and $255. At $175.15, DHR trades at a steep discount to even the most conservative of those targets — a gap that reflects how hard the stock has been hit rather than analyst bearishness on the business.
The print on May 5 will test whether Danaher's life sciences recovery is gathering real momentum or whether the China and biopharma headwinds are extending the trough longer than the Street's models assumed.
See the live data behind this article on ORTEX.
Open DHR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
